- [Resource Hub](/)
- [Resource](/?resource-type=poster#library)
- A direct amplicon-based targeted sequencing assay for mutation analysis of single circulating tumor cells and correlation with circulating tumor DNA

# A direct amplicon-based targeted sequencing assay for mutation analysis of single circulating tumor cells and correlation with circulating tumor DNA

Because a single cell holds only about 6 pg of DNA, mutation analysis of circulating tumor cells has usually required whole genome amplification first; this AACR 2020 poster reports an amplicon panel run directly on cell lysate and compares the mutations it found in single CTCs against matched circulating tumor DNA.

Presented by RareCyte and the University of Washington.

Read or download to see:

- Running the amplicon panel directly on cell lysate, with no prior whole genome amplification, raised median read depth 48-fold. Across single model CTCs, 23 of 29 variants (79%) present in bulk A549 genomic DNA were recovered without WGA, against 15 of 29 (52%) after it, and the false positive error frequency was 8-fold lower and the false negative error frequency 2-fold lower than the WGA method.

- In each of two metastatic breast cancer patients, a known mutation was detected in 3 of 5 single CTCs and in 0% of the matched white blood cells. One patient’s CTCs carried PIK3CA E542K, a well-documented oncogenic mutation; the other’s carried ERBB2 L755S, which confers resistance to common anti-HER2 therapies, in a tumor that had presented as mixed invasive ductal (HER2+) and lobular (HER2-) carcinoma with differential HER2 expression.

- The same variants were present in each patient’s cell-free DNA at similar allele frequencies, whichever manufacturer’s blood collection tube the plasma came from. PIK3CA E542K read 63% in cell-free DNA from both the RareCyte tube and the Streck tube, and ERBB2 L755S read 21% from the RareCyte tube against 25% from the Streck tube, so the single-cell calls and the circulating tumor DNA agreed in both patients.

[Download poster](https://cdn.sanity.io/files/s3p6uqps/production/620b26e37450b92a8ce64be315bb8bdce204e7bd.pdf)

Your browser doesn’t support embedded PDFs.
[Download the poster](https://cdn.sanity.io/files/s3p6uqps/production/620b26e37450b92a8ce64be315bb8bdce204e7bd.pdf) to view it.

[Back to all resources](/#library)
## Related resources
[Publication](https://doi.org/10.1200/JCO.2026.44.16_suppl.5041) CyteFinder Journal of Clinical Oncology 2026
### Clinical validation of circulating tumor cell synaptophysin and androgen receptor expression in metastatic prostate cancer phenotypes.
[View Publication](https://doi.org/10.1200/JCO.2026.44.16_suppl.5041) [Video](https://www.youtube.com/watch?v=_oGC1KRVN2U) CyteFinder 2026
### Dr. Pashtoon Kasi on the impact of circulating tumor cells on clinical research
[Watch Video](https://www.youtube.com/watch?v=_oGC1KRVN2U) [Publication](https://pmc.ncbi.nlm.nih.gov/articles/PMC12881594/) CyteFinder Nature Communications 2026
### Extracellular matrix mediates circulating tumor cell clustering in triple-negative breast cancer metastasis
[View Publication](https://pmc.ncbi.nlm.nih.gov/articles/PMC12881594/) [Publication](https://doi.org/10.1016/j.ejso.2025.111357) CyteFinder European Journal of Surgical Oncology 2026
### Circulating tumor cells predict relapse in head and neck mucosal squamous cell carcinoma
[View Publication](https://doi.org/10.1016/j.ejso.2025.111357) [Publication](https://pmc.ncbi.nlm.nih.gov/articles/PMC12805936/) CyteFinder Cancer Research Communications 2026
### Surface Marker Identification to Capture Live Circulating Tumor Cells in Metastatic Triple-Negative Breast Cancer
[View Publication](https://pmc.ncbi.nlm.nih.gov/articles/PMC12805936/) [Publication](https://doi.org/10.3390/cancers17162717) CyteFinder Cancers 2025
### Comprehensive Longitudinal Linear Mixed Modelling of CTCs Illuminates the Role of Trop2, EpCAM, and CD45 in CTC Clustering and Metastasis
[View Publication](https://doi.org/10.3390/cancers17162717) [Publication](https://doi.org/10.1080/07366205.2025.2534299) CyteFinder BioTechniques 2025
### A novel device for buffy coat collection
[View Publication](https://doi.org/10.1080/07366205.2025.2534299) [Poster](https://cdn.sanity.io/files/s3p6uqps/production/246a94d07c9a47c844784f113f57f4415bf84a5c.pdf) CyteFinder 2025
### Development of a CTC Based Assay to Characterize MAOA Expression in Metastatic Prostate Cancer
[Download Poster](https://cdn.sanity.io/files/s3p6uqps/production/246a94d07c9a47c844784f113f57f4415bf84a5c.pdf) [Poster](https://cdn.sanity.io/files/s3p6uqps/production/43fb6d4a8510166e936d250b3bf172e2f669bfa3.pdf) CyteFinder 2025
### Quantitative analysis of HER2, HER3, and γH2AX expression on circulating tumor cells for pharmacodynamic measurement in clinical trials
[Download Poster](https://cdn.sanity.io/files/s3p6uqps/production/43fb6d4a8510166e936d250b3bf172e2f669bfa3.pdf) [Publication](https://pmc.ncbi.nlm.nih.gov/articles/PMC11985722/) CyteFinder Cellular and Molecular Life Sciences 2025
### Portal venous circulating tumor cells as a biomarker for relapse prediction in resected pancreatic cancer
[View Publication](https://pmc.ncbi.nlm.nih.gov/articles/PMC11985722/) [Publication](https://pmc.ncbi.nlm.nih.gov/articles/PMC12092302/) CyteFinder Nature Medicine 2025
### Neoadjuvant triplet immune checkpoint blockade in newly diagnosed glioblastoma
[View Publication](https://pmc.ncbi.nlm.nih.gov/articles/PMC12092302/) [Poster](https://cdn.sanity.io/files/s3p6uqps/production/f6e029d0a3ad855ff644046c0b1c1c20cf771df2.pdf) CyteFinder Orion 2024
### Next Gen Liquid Biopsy: Comprehensive Analysis from a Single Tube of Blood
[Download Poster](https://cdn.sanity.io/files/s3p6uqps/production/f6e029d0a3ad855ff644046c0b1c1c20cf771df2.pdf)